Asset profile
Sotorasib
Small molecule
Evidence outlook
Accelerated approval: Non-Small Cell Lung Cancer (label: locally advanced or metastatic NSCLC with KRAS G12C mutation following at least one prior systemic...)
Accelerated approval is granted on surrogate endpoints; confirmatory clinical benefit is being verified in ongoing trials. Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
69 competitors in this universe: 9 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Sotorasib: this drug | Approved | Small molecule | KRAS G12C | ||
| Calderasib | Phase 3 | Small molecule | KRAS G12C | ||
| Divarasib | Phase 3 | Small molecule | KRAS G12C | ||
| Fulzerasib | Phase 3 | Small molecule | KRAS G12C | ||
| Glecirasib | Phase 3 | Small molecule | KRAS G12C | ||
| JMKX001899 | Phase 3 | Small molecule | KRAS G12C | ||
| Elironrasib | Phase 1/2 | Small molecule | KRAS G12C | ||
| FMC-376 | Phase 1/2 | Small molecule | KRAS G12C | ||
| BBO-8520 | Phase 1 | Small molecule | KRAS G12C | ||
| HBI-2438 | Phase 1 | Small molecule | KRAS G12C | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A |
…and 54 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
3 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(24 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (4)
October 2026 (1)
What to watch
November 2026 (1)
What to watch
December 2026 (2)
What to watch
What to watch
2027 (11)
April 2027 (1)
What to watch
May 2027 (1)
What to watch
June 2027 (2)
What to watch
What to watch
August 2027 (3)
What to watch
What to watch
What to watch
October 2027 (1)
What to watch
November 2027 (1)
What to watch
2028 (4)
January 2028 (1)
July 2028 (1)
What to watch
September 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (2)
June 2029 (1)
What to watch
September 2029 (1)
What to watch
2030 (3)
June 2030 (1)
What to watch
July 2030 (1)
What to watch
August 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.